7/10/2013

The American Society of Clinical Oncology issued new practice guidelines urging physicians to discuss the use of so-called chemopreventive drugs with their female patients at high risk of breast cancer. Doctors should explain the risks and benefits of tamoxifen for high-risk premenopausal women, and those of tamoxifen, raloxifene and exemestane for high-risk postmenopausal women. The recommendations were published in the Journal of Clinical Oncology.

Full Story:
HealthDay News

Related Summaries